Results 141 to 150 of about 1,341 (168)

Ototoxicity and Teprotumumab

Annals of Otology, Rhinology & Laryngology, 2021
Objectives: Teprotumumab, a novel monoclonal antibody, targets the insulin-like growth factor 1 (IGF-1) receptor. IGF-1 receptors, found in muscle and fat adjacent to the eye and implicated in Graves Ophthalmopathy, are also in the cochlea.
Julie Highland, Steven Gordon, Deepika Reddy, Neil Patel   +3 more
openaire   +2 more sources

Teprotumumab

Reactions Weekly, 2022
Caroline Y. Yu, Jamie A. Keen, Erin M. Shriver   +2 more
  +7 more sources

Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity [PDF]

Journal of Clinical Endocrinology and Metabolism, 2023
CONTEXT: Early inflammatory thyroid eye disease (TED) can lead to symptomatic chronic disease, including disabling proptosis. Teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, previously demonstrated efficacy in acute, high ...
Raymond S Douglas, Michael Karon, Sara Wester   +2 more
exaly   +2 more sources

Patterns of Teprotumumab‐Induced Hearing Dysfunction: A Systematic Review

Otolaryngology - Head and Neck Surgery
Abstract Objective Hearing loss has been reported after administration of the monoclonal antibody teprotumumab. The purpose of this study was to review available evidence regarding the patterns of teprotumumab‐related ototoxicity. Data Sources PubMed, EMBASE, and Cochrane Library.
Tiffany Peng Hwa
exaly   +2 more sources

Teprotumumab

Reactions Weekly, 2023
  +7 more sources

Teprotumumab-Related Hyperglycemia

The Journal of Clinical Endocrinology & Metabolism, 2022
Abstract Context Graves orbitopathy (GO) or thyroid eye disease is a potentially sight-threatening and disfiguring autoimmune disease. Teprotumumab is a monoclonal antibody against the insulin-like growth factor-I receptor that was recently approved for GO treatment.
Linus Amarikwa, Abubakr Mohamed, Sun H Kim, Andrea Lora Kossler, Chrysoula Dosiou   +4 more
openaire   +2 more sources

Teprotumumab and Hyperglycemia Guidelines to Monitor for Hyperglycemia in Teprotumumab

Ophthalmic Plastic & Reconstructive Surgery, 2021
H B Harold, Lee, Cary N, Mariash, Michael K, Yoon, Irina, Belinsky, Francis X, Creighton, Nicholas, Mahoney, Carisa K, Petris, Alison B, Callahan, Ashley A, Campbell, Michael, Kazim, Lora R, Dagi Glass   +10 more
openaire   +2 more sources

The Adverse Effects Profile of Teprotumumab

Journal of Clinical Endocrinology and Metabolism, 2023
Marius Stan, Christine Krieger
exaly  

Teprotumumab-Related Hyperglycemia

Journal of Clinical Endocrinology and Metabolism, 2023
Sun Kim, Andrea Kössler, Chrysoula Dosiou   +2 more
exaly  

Teprotumumab for chronic thyroid eye disease

Orbit, 2022
Liane Dallalzadeh, Daniel J Ozzello
exaly